Matthew J. Dean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matthew J. Dean has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Maria Dulfary Sanchez-Pino
Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA
21 shared publications - Amirsalar Mansouri
Department of Interdisciplinary Oncology, Louisiana State University (LSU) Health School of Medicine-New Orleans, New Orleans, LA 70112, USA
20 shared publications - Augusto C. Ochoa
Louisiana State University Health Sciences Center 9 New Orleans, LA
20 shared publications - Darwin Chang
H. Lee Moffitt Cancer Center and Research Institute 5 Department of Immunology Tampa, Florida
20 shared publications - Dorota Wyczechowska
Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA
20 shared publications - Jessica K. Mandula
H. Lee Moffitt Cancer Center and Research Institute 5 Department of Immunology Tampa, Florida
20 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
GPR84 receptor modulation reduces apoptosis in CD8+ T cells.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
GPR84 receptor modulation reduces apoptosis in CD8+ T cells.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
GPR84 antagonism improves anti-tumor therapeutic vaccine efficacy in an in vivo multi-boost immunization regimen.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
GPR84 antagonism improves anti-tumor therapeutic vaccine efficacy in an in vivo multi-boost immunization regimen.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Top 50 differentially expressed genes between GLPG1205 and DMSO in CD8+ T cells.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Top 50 differentially expressed genes between GLPG1205 and DMSO in CD8+ T cells.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Top 50 differentially expressed genes between DL175 and DMSO in CD8+ T cells.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Top 50 differentially expressed genes between DL175 and DMSO in CD8+ T cells.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
BM-MDSCs express more GPR84 mRNA compared to T cells.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
BM-MDSCs express more GPR84 mRNA compared to T cells.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Validation of CRISPR-Cas9 and Global GPR84 knockout.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Validation of CRISPR-Cas9 and Global GPR84 knockout.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Unsupervised clustering of single-cell RNA sequencing.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Unsupervised clustering of single-cell RNA sequencing.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Human GPR84 protein expression level correlate with T cell activation.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
Human GPR84 protein expression level correlate with T cell activation.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
GPR84 modulation regulates T cell cytokine and chemokine secretion.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
GPR84 modulation regulates T cell cytokine and chemokine secretion.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
G protein–coupled receptor 84 (GPR84) is a medium-chain free fatty acid receptor predominantly expressed in myeloid cells. Previous studies have identified GPR84 as an enhancer of the pro-inflammatory myeloid cell responses and a regulator of metabolic homeostasis. However, the role of GPR84 in T-cell function and metabolism remains largely unexplored. This study tested the effect of GPR84 modulation on CD8+ T-cell function and metabolism in vitro and examined its effect on antitumor function in adoptive cellular therapy models. Pharmacologic antagonism with GLPG1205 or genetic deletion of GPR84 promoted T-cell differentiation, proliferation, cytokine production, and cytotoxicity, whereas agonism with DL175 reduced these functions. These functional changes were paralleled by changes in metabolic activity. Antagonism and genetic deletion increased glucose uptake, glycolysis, oxidative phosphorylation, and ATP production, which enhanced the overall cell energetic fitness, whereas agonism resulted in a quiescent energetic profile. Furthermore, antagonism or deletion of GPR84 in antigen-specific CD8+ T cells in adoptive cellular therapy models enhanced their antitumor effects in vivo. Thus, GPR84 inhibition improves CD8+ T-cell function and may further enhance adoptive cellular therapies.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming
G protein–coupled receptor 84 (GPR84) is a medium-chain free fatty acid receptor predominantly expressed in myeloid cells. Previous studies have identified GPR84 as an enhancer of the pro-inflammatory myeloid cell responses and a regulator of metabolic homeostasis. However, the role of GPR84 in T-cell function and metabolism remains largely unexplored. This study tested the effect of GPR84 modulation on CD8+ T-cell function and metabolism in vitro and examined its effect on antitumor function in adoptive cellular therapy models. Pharmacologic antagonism with GLPG1205 or genetic deletion of GPR84 promoted T-cell differentiation, proliferation, cytokine production, and cytotoxicity, whereas agonism with DL175 reduced these functions. These functional changes were paralleled by changes in metabolic activity. Antagonism and genetic deletion increased glucose uptake, glycolysis, oxidative phosphorylation, and ATP production, which enhanced the overall cell energetic fitness, whereas agonism resulted in a quiescent energetic profile. Furthermore, antagonism or deletion of GPR84 in antigen-specific CD8+ T cells in adoptive cellular therapy models enhanced their antitumor effects in vivo. Thus, GPR84 inhibition improves CD8+ T-cell function and may further enhance adoptive cellular therapies.